ArticleCureus2025
Isolated Vertigo as an Early Sign of Anti-GQ1b-Positive Miller Fisher Syndrome: Expanding the Spectrum.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Miller Fisher syndrome (MFS) occupies a distinct corner of Guillain-Barré syndrome (GBS), typically presenting with a triad comprising ophthalmoplegia, ataxia, and areflexia. While diplopia and limb incoordination are typically early features, isolated vertigo as a prodromal symptom is exceedingly uncommon and often misdiagnosed as benign vestibular disease. We report a 56-year-old Malay man who presented twice to the emergency department with acute, continuous vertigo and was initially treated symptomatically before subsequently developing bilateral ophthalmoplegia and ataxia. Anti-ganglioside (anti-GQ1b) antibody testing was positive, confirming the diagnosis of MFS, and electrophysiological studies revealed early GBS-spectrum changes. The patient responded well to intravenous immunoglobulin (IVIG) and made a full recovery within six weeks. This case illustrates that vestibular symptoms can occur early within the anti-GQ1b spectrum and may easily be overlooked. It also underscores the importance of careful, repeated neurological and ophthalmological examinations. Early recognition and treatment are critical to ensuring successful recovery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.